Literature DB >> 12765811

Growth potential of prolactinomas in men: is it really different from women?

Hiroshi Nishioka1, Jo Haraoka, Kiyohiro Akada.   

Abstract

BACKGROUND: In comparison to prolactinomas in women, those in men are usually large tumors and have been suggested to have a higher proliferation activity. To elucidate the reason for the predominance of large tumors in men, we investigated the gender-related difference of prolactinomas including growth potential.
METHODS: We conducted a retrospective study comparing unselected 16 men and 27 women with prolactinoma concerning clinical and endocrine findings, tumor volume, and the mean Ki-67 (MIB-1) positive cell index (PCI).
RESULTS: Prolactinomas in men were larger in size (p = 0.0090), higher in serum prolactin level (p = 0.0359), and exhibited higher PCI (p = 0.0138) than those in women. However, the three factors-tumor volume, prolactin level, and the PCI-showed positive correlations with each other. There was no gender-related difference in the PCI when small tumors (<1.0 cm3) were excluded.
CONCLUSION: High PCI is associated with large tumors in both men and women. Because large tumors predominate in men, this is in fact consistent with the view that the biologic behavior of prolactinomas is different between the sexes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12765811     DOI: 10.1016/s0090-3019(03)00012-0

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  13 in total

1.  Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.

Authors:  Arijit Chattopadhyay; Anil Bhansali; Shariq R Masoodi
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference.

Authors:  Julie Kreutz; Laurent Vroonen; Francoise Cattin; Patrick Petrossians; Albert Thiry; Liliya Rostomyan; Luaba Tshibanda; Albert Beckers; Jean-François Bonneville
Journal:  Neuroradiology       Date:  2015-04-07       Impact factor: 2.804

3.  Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Authors:  Fatemeh Mahboobifard; Farahnaz Bidari-Zerehpoosh; Zahra Davoudi; Mahshid Panahi; Leila Dargahi; Mohammad H Pourgholami; Gieve Sharifi; Neda Izadi; Masoumeh Jorjani
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

4.  Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.

Authors:  Sema Ciftci Dogansen; Gulsah Yenidunya Yalin; Seher Tanrikulu; Sakin Tekin; Nihan Nizam; Bilge Bilgic; Serra Sencer; Sema Yarman
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

Review 5.  The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas.

Authors:  M Victoria Recouvreux; M Andrea Camilletti; Daniel B Rifkin; Graciela Díaz-Torga
Journal:  J Endocrinol       Date:  2015-12-23       Impact factor: 4.286

6.  Giant prolactinomas in adolescence: an uncommon cause of blindness.

Authors:  Patrick Semple; Graham Fieggen; Jeannette Parkes; Naomi Levitt
Journal:  Childs Nerv Syst       Date:  2006-09-16       Impact factor: 1.475

7.  Expression of estrogen receptor α and growth factors in human prolactinoma and its correlation with clinical features and gender.

Authors:  H Lv; C Li; S Gui; Y Zhang
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 8.  How to investigate and treat: headache and hyperprolactinemia.

Authors:  Gennaro Bussone; Susanna Usai; Franca Moschiano
Journal:  Curr Pain Headache Rep       Date:  2012-08

9.  Expression of laminin beta2: a novel marker of hypoxia in pituitary adenomas.

Authors:  Yijun Bao; Daizo Yoshida; Daijiro Morimoto; Akira Teramoto
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

10.  Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression.

Authors:  Ilan Shimon; Carlos Benbassat; Gloria Tzvetov; Simona Grozinsky-Glasberg
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.